Search Results

NeuroLogica Corp. announces its OmniTom Elite PCD has received an Innovative Technology designation from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country.

NeuroLogica Announces FDA 510(k) Clearance of BodyTom ® 64.

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced the first installation of its SmartMSU™ with OmniTom® Elite – a specialized ambulance that is equipped with a small computed tomography (CT) scanner for head imaging – in the Asia-Pacific region.

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced a partnership with The University of Dundee in Scotland, United Kingdom, to collaborate on research using the OmniTom® Elite with Photon Counting Detector computed tomography imaging technology.

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced today that its state-of-the-art Elite Mobile Computed Tomography (CT) systems have received the European Union (EU) CE marking via compliance with the new EU Medical Device Regulation (MDR 2017/745).

The world of medical imaging is no longer just black & white. NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced today its state-of-the-art OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology.

Samsung NeuroLogica Corp. today announced that it received the Risk Management Framework approval, Authority to Operate (ATO) from the Defense Health Agency for its RS85 Prestige Ultrasound.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

NeuroLogica Corp. announced today the immediate availability of its SmartMSU™ with OmniTom® Elite CT scanner. This next-generation Mobile Stroke Unit (MSU) advances the technology available for stroke imaging on an ambulance that the company pioneered 10 years ago

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.